Israel’s OncoHost Wins 2025 Precision Oncology Award for AI-Based Cancer Treatment

Original source here

PROphet® uses a blood test to analyze thousands of plasma proteins and predict how patients are likely to respond to immunotherapy.

Israeli American biotech firm OncoHost has been named the Top Precision Oncology Solution for 2025 by Life Sciences Review, marking a major recognition of its work in tailoring cancer treatment through artificial intelligence and proteomics.

The award, announced in the magazine’s annual therapeutics edition, followed nominations from industry peers, a panel of senior executives and a review by the publication’s editorial board.

At the center of the recognition is OncoHost’s platform, PROphet®, which uses a blood test to analyze thousands of plasma proteins and predict how patients are likely to respond to immunotherapy.

The system provides doctors with forecasts on treatment benefit, potential resistance and possible side effects, aiming to guide decisions that are more personalized and effective.

“Being named the leading precision oncology solution is an important milestone,” Dr. Ofer Sharon, OncoHost’s CEO said in a press release. “Our approach shifts attention from the tumor alone to the broader biological environment of the patient.”

The company’s first clinical product, PROphetNSCLC™, supports treatment planning for advanced non-small cell lung cancer.

It is used alongside PD-L1 and genomic testing to identify patients less likely to benefit from immune checkpoint inhibitors.

OncoHost is also developing additional tools, including PROphetirAE™, which seeks to predict severe immune-related side effects, and platforms aimed at renal cell carcinoma and melanoma.

With headquarters in Binyamina, Israel, and Cary, North Carolina, the company backs its technology with one of the largest prospective trials in the field.

Its research combines proteomics, the large-scale study of proteins, with advanced machine learning to build predictive models intended to improve survival outcomes.

Life Sciences Review, a U.S.-based print and digital magazine, highlighted OncoHost as part of its focus on innovators reshaping biotechnology, pharmaceuticals and healthcare.

The award reinforces OncoHost’s growing role in precision medicine, where AI-driven analysis is being used to refine cancer care strategies and improve patient outcomes.

‍